Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
Effective therapies for the so-called atypical parkinsonian syndrome (APS) such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal syndrome (CBS) are not available. Dopamine agonists (DA) are not often used in APS because of inefficacy and in a minority of case,...
Main Authors: | Moretti, Davide Vito, Binetti, Giuliano, Zanetti, Orazio, Frisoni, Giovanni Battista |
---|---|
Format: | Online |
Language: | English |
Published: |
Frontiers Media S.A.
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046164/ |
Similar Items
-
Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
by: Moretti, Davide Vito, et al.
Published: (2014) -
Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
by: Moretti, Davide V., et al.
Published: (2014) -
Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease
by: Moretti, Davide V., et al.
Published: (2011) -
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
by: Kim, Han-Joon, et al.
Published: (2011) -
Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
by: Zhou, Chang-Qing, et al.
Published: (2013)